Trials / Terminated
TerminatedNCT04442126
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Numab Therapeutics AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Squamous Cell Carcinoma
- Ovarian Carcinoma
- Peritoneal Carcinoma
- Fallopian Tube Cancer
- Head and Neck Squamous Cell Carcinoma
- Triple Negative Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NM21-1480 | Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein |
Timeline
- Start date
- 2020-08-19
- Primary completion
- 2024-02-06
- Completion
- 2024-02-06
- First posted
- 2020-06-22
- Last updated
- 2025-05-23
- Results posted
- 2025-05-23
Locations
26 sites across 3 countries: United States, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04442126. Inclusion in this directory is not an endorsement.